Advertisement
Document › Details
Sangamo Therapeutics, Inc.. (11/18/19). "Press Release: Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference". Brisbane, CA.
Region | London, Greater London | |
Country | United Kingdom (GB) | |
Organisation | Sangamo Therapeutics Inc. (Nasdaq: SGMO) | |
Group | Sangamo (Group) | |
Organisation 2 | Jefferies LLC | |
Group | Leucadia (Group) | |
Product | Jefferies 2019 London Healthcare Conference | |
Product 2 | cell therapy | |
Index term | Sangamo–Leucadia: investor conference, 201911 supply service Sangamo at Jefferies London Healthcare Conference 2019 | |
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London, UK.
The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com.
Investor Relations – Global
McDavid Stilwell
510-970-6000, x219
[email protected]
Media Inquiries – Global
Aron Feingold
510-970-6000, x421
[email protected]
Record changed: 2023-06-05 |
Advertisement
More documents for Sangamo (Group)
- [1] Sangamo Therapeutics, Inc.. (8/6/24). "Press Release: Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases". Richmond, CA....
- [2] MorphoSys AG. (1/6/21). "Press Release: MorphoSys Appoints Sung Lee as Chief Financial Officer". Planegg....
- [3] Mogrify Ltd.. (4/21/20). "Press Release: Mogrify and Sangamo Announce Collaboration and Exclusive License Agreement for Mogrify’s iPSC- and ESC-derived Regulatory T Cells". Cambridge & Brisbane, CA....
- [4] Sangamo Therapeutics, Inc.. (11/19/19). "Press Release: Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation". Brisbane, CA....
- [5] Sangamo Therapeutics, Inc.. (11/1/19). "Press Release: Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer". Brisbane, CA....
- [6] Sangamo Therapeutics, Inc.. (7/31/19). "Press Release: Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel". Brisbane, CA....
- [7] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo Announces Agreement Securing Access To Large-scale, Commercial-grade Manufacturing Capacity at Brammer Bio". Brisbane, CA....
- [8] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy". Brisbane, CA & New York, NY....
- [9] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data". Brisbane, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top